1. AFP, age, and pathologic tumor stage were predictive for OS (p < 0.0001).2. RFS was worse in AFPP-GC patients (p = 0.002).3. Recurrence was more frequent in AFPP-GC patients (34.5%) than in AFPN-GC patients (16.9%).4. Five-year survival rate was lower in AFPP-GC patients (57.9%) than in AFPN-GC patients (76.1%).5. Five-year RFS rate was lower in AFPP-GC patients (53%) than in AFPN-GC patients (76%). This evidence concerns the gene AFP and gastric cancer.